BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 31228096)

  • 1. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
    Masarova L; Bose P; Verstovsek S
    Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.
    Economides MP; Verstovsek S; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Oct; 14(5):460-468. PubMed ID: 31372878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
    Hasselbalch HC; Holmström MO
    Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
    Barosi G; Lupo L; Rosti V
    Curr Hematol Malig Rep; 2012 Mar; 7(1):50-6. PubMed ID: 22278747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutics in myeloproliferative neoplasms.
    Venugopal S; Mascarenhas J
    J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.
    Kaplan JB; Stein BL; McMahon B; Giles FJ; Platanias LC
    EBioMedicine; 2016 Jan; 3():17-25. PubMed ID: 26870834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for myeloproliferative neoplasms (MPN).
    Hofmann S; Babiak A; Greiner J
    Curr Cancer Drug Targets; 2011 Jan; 11(1):72-84. PubMed ID: 21062247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Yung Y; Lee E; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
    Mesa RA; Scherber RM; Geyer HL
    Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.